Back to top
more

Zymeworks (ZYME)

(Real Time Quote from BATS)

$16.96 USD

16.96
561,309

+1.35 (8.65%)

Updated Nov 7, 2024 01:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Zymeworks (ZYME) delivered earnings and revenue surprises of 2.50% and 12.98%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

GSK (GSK) Q3 Earnings Surpass Estimates

by Zacks Equity Research

Glaxo (GSK) delivered earnings and revenue surprises of 9.48% and 2.16%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Zymeworks (ZYME) delivered earnings and revenue surprises of 3.70% and 16.93%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

AnaptysBio (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Zymeworks (ZYME) delivered earnings and revenue surprises of -35.48% and 44.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Tirthankar Chakraborty headshot

3 Top Stocks to Invest in for Amazing Earnings Acceleration

by Tirthankar Chakraborty

Invest in companies such as Zymeworks (ZYME), Evolus (EOLS) and Bilibili (BILI) for superb earnings acceleration.

Zymeworks (ZYME) Loses -13.41% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Zymeworks (ZYME) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zymeworks (ZYME) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Zymeworks (ZYME) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 48.72% and 7.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Zymeworks Inc. (ZYME) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MannKind (MNKD) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

MannKind (MNKD) delivered earnings and revenue surprises of 300% and 11.67%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks Inc. (ZYME) Is Up 1.64% in One Week: What You Should Know

by Zacks Equity Research

Does Zymeworks Inc. (ZYME) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does Zymeworks Inc. (ZYME) Have the Potential to Rally 42.84% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 42.8% in Zymeworks Inc. (ZYME). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 64.61% Upside in Zymeworks Inc. (ZYME): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 64.6% upside potential for Zymeworks Inc. (ZYME). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zymeworks Inc. (ZYME) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -49.02% and 45.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

ANI (ANIP) delivered earnings and revenue surprises of 100% and 20.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Cytek Biosciences, Inc. (CTKB) Q2 Earnings Lag Estimates

by Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of -66.67% and 6.83%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 16.67% and 7.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

New Strong Buy Stocks for July 26th

by Zacks Equity Research

ANGI, SFIX, ZVIA, ZYME and HOWL have been added to the Zacks Rank #1 (Strong Buy) List on July 26, 2023.

Caribou Biosciences, Inc. (CRBU) Surges 45.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

Caribou Biosciences, Inc. (CRBU) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 42.19% and 307.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Regeneron (REGN) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Regeneron (REGN) delivered earnings and revenue surprises of 9.08% and 8.12%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Zymeworks Inc. (ZYME) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.